Search clinical trials for: LINE

Total 8922 results

Medical Directions, Inc
University of Miami; University of Arizona; Cleveland Clinic Florida; Contra Costa... and other collaborators

Completed

Online Primary Care Physician (PCP) Training in Screening, Brief Intervention, Referral, and Treatment

Medical Education

United States
Genta Incorporated

Unknown

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer (TESEGAST)

Gastric Carcinoma

Taiwan, United States, Germany
Genta Incorporated

Unknown

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Breast Neoplasm

United States
Alaunos Therapeutics

Withdrawn

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Lymphoma
Translational Drug Development
Stand Up To Cancer; American Association for Cancer Research; Scottsdale Healthcare

Completed

A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

Previously Treated Metastatic Pancreatic Cancer

United States
Yanqiao Zhang

Unknown

Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients

Gastric Adenocarcinoma
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

Tongue Cancer | Recurrent Colon Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral... and other conditions

United States
Hopital Lariboisière

Completed

Decrease the Frequency of Inappropriate Intravenous Lines in Internal Medicine (PERMI)

Acute Medical Patients Hospitalized in Internal Medicine
Steven E. Coutre

Completed

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Leukemia | Acute Lymphocytic Leukemia | Leukemia, Lymphocytic

United States
Pfizer

Completed

Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

Vancomycin Resistance Enterococcus Faecium
Pfizer

Completed

Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)

Staphylococcal Infections
AGO Study Group

Completed

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

Epithelial Ovarian Cancer

Germany
National Taiwan University Hospital

Completed

The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection

Helicobacter Pylori Infection

Taiwan
AstraZeneca

Completed

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Heart Failure | Ventricular Dysfunction, Left

Sweden
National Cancer Center, Korea
AstraZeneca

Unknown

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Adenocarcinoma | Non Small Cell Lung Cancer

Korea, Republic of
Vejle Hospital

Completed

Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

Metastatic Colorectal Cancer

Denmark
Boston Medical Center
National Cancer Institute (NCI)

Completed

Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia

Leukemia

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Head and Neck Cancer | Lung Cancer

United States
AstraZeneca

Completed

An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon (CEPHEUS)

High Blood Cholesterol
Eli Lilly and Company

Completed

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Novartis Pharmaceuticals

Withdrawn

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Metastatic Breast Cancer
Eli Lilly and Company

Completed

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

Endometrial Cancer

United States
AstraZeneca

Completed

Iressa as Second Line Therapy in Advanced NSCLC-Asia (ISTANA)

NSCLC

Korea, Republic of
Swiss Group for Clinical Cancer Research

Completed

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Switzerland
Technical University of Munich

Withdrawn

Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Breast Cancer

Germany
Genta Incorporated

Unknown

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Non-resectable Breast Cancer

United States
Telik

Completed

Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
University of Regensburg
ClinAssess GmbH

Unknown

Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial (MM03)

Multiple Myeloma

Germany
Federal University of São Paulo

Completed

Post-bariatric Abdominoplasty: Skin Sensation Evaluation

Obesity | Hypesthesia

Brazil
Mayo Clinic

Completed

Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)

Hypercholesterolemia

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus

Esophageal Cancer

United States
Fudan University

Completed

Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer

Esophageal Squamous Cell Carcinoma
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Liver Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

Prostate Cancer

United States
Pfizer
University of Maryland; Lodise & Lodise, LLC

Completed

Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients

Complicated Skin and Structure Infection | Nosocomial Pneumonia
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer

Esophageal Cancer
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Charite University, Berlin, Germany
Aesculap AG

Unknown

Joint Line Reconstruction in Navigated Total Knee Arthroplasty Revision (NavRevKnie)

Revision Total Knee Arthroplasty Because of | Loosening | Instability | Impingement | or Other Reasons Accepted as Indications for TKA Exchange. | The Focus is to Determine the Precision of Joint Line Restoration in Navigated vs. Conventional Revision Total Knee Arthroplasty

Germany
Daiichi Sankyo, Inc.

Completed

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer

Head and Neck Cancer | Radiation Toxicity | Oral Complications

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Sociedad Española de Neumología y Cirugía Torácica

Completed

Efficacy of "On Line" Telematic Spirometry

Chronic Obstructive Pulmonary Disease

Spain
Daiichi Sankyo, Inc.

Completed

Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States, Canada, Puerto Rico
Daiichi Sankyo, Inc.

Completed

DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma

Colorectal Cancer

United States
Veeda Oncology
Bayer; Celgene Corporation

Terminated

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Withdrawn

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Veeda Oncology
Bristol-Myers Squibb

Completed

A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Veeda Oncology
Celgene Corporation

Completed

A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Paratek Pharmaceuticals Inc

Withdrawn

Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Skin Structures and Soft Tissue Infections

3

Subscribe